Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0LB0X
|
||||
| Former ID |
DIB018009
|
||||
| Drug Name |
KH064
|
||||
| Synonyms |
sPLA2-2A inhibitor, compound 2b
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Breast cancer [ICD9: 174, 175; ICD10:C50] | Clinical trial | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C31H37NO4
|
||||
| InChI |
InChI=1S/C31H37NO4/c33-30(16-10-2-1-5-11-25-12-6-3-7-13-25)32-28(19-22-31(34)35)23-26-17-20-29(21-18-26)36-24-27-14-8-4-9-15-27/h3-4,6-9,12-15,17-18,20-21,28H,1-2,5,10-11,16,19,22-24H2,(H,32,33)(H,34,35)/t28-/m0/s1
|
||||
| InChIKey |
KWLUIYFCMHKLKY-NDEPHWFRSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Phospholipase A2, membrane associated | Target Info | Inhibitor | [1] | |
| BioCyc Pathway | Phospholipases | ||||
| KEGG Pathway | Glycerophospholipid metabolism | ||||
| Ether lipid metabolism | |||||
| Arachidonic acid metabolism | |||||
| Linoleic acid metabolism | |||||
| alpha-Linolenic acid metabolism | |||||
| Metabolic pathways | |||||
| Ras signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Pancreatic secretion | |||||
| Fat digestion and absorption | |||||
| Pathway Interaction Database | Glypican 1 network | ||||
| Reactome | Acyl chain remodelling of PC | ||||
| Acyl chain remodelling of PE | |||||
| Acyl chain remodelling of PI | |||||
| WikiPathways | Cardiac Hypertrophic Response | ||||
| Glycerophospholipid biosynthesis | |||||
| Glycerophospholipid Biosynthetic Pathway | |||||
| Spinal Cord Injury | |||||
| Eicosanoid Synthesis | |||||
| MicroRNAs in cardiomyocyte hypertrophy | |||||
| References | |||||
| REF 1 | D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 2003 Mar 3;4(2-3):181-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.